Ignite Creation Date:
2024-05-06 @ 4:49 PM
Last Modification Date:
2024-10-26 @ 2:16 PM
Study NCT ID:
NCT05098197
Status:
RECRUITING
Last Update Posted:
2024-04-18
First Post:
2021-10-12
Brief Title:
Study on TIL for the Treatment of Advanced Hepatobiliary-Pancreatic Cancers
Sponsor:
Shanghai Juncell Therapeutics
Organization:
Shanghai Juncell Therapeutics
Study Overview
Official Title:
A Clinical Study on TIL for the Treatment of Advanced Hepatobiliary-Pancreatic Cancers
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte TIL therapy in patients with advanced hepatobiliary-pancreatic cancers Autologous TILs are expanded from tumor resections or biopsies and infused iv into the patient after NMA lymphodepletion treatment with hydroxychloroquine600mgsingle-dose and cyclophosphamide
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None